PamGene is a Dutch biotechnology company that specializes in multiplex kinase activity profiling technology. The company provides contract research services and diagnostic assay services to support physicians and scientists in understanding diseases and improving patient treatment. PamGene's technology measures real-time cellular kinome activity, resulting in comprehensive and accurate data that can be used in clinical, translational, and pre-clinical settings to gain insights into discriminative drug responses, analyze and optimize kinase inhibitors, and discover novel biomarkers, targets, and pathways. The company's services include biomarker discovery, patient stratification, and therapy selection for oncological diseases, and its Diagnostic Assay Services facility is ISO13485 compliant.

PamGene has developed new applications on her patented technology platform that measures cellular kinase activity as well as nuclear receptor activity broadly. This enables more understanding of drug interactions with these important classes of signalling molecules.

PamGene's technology is widely in use in support of drug R&D for elucidation of drug-target interactions and in support of clinical trials as a drug activity based biomarker platform, which is a paradigm shift from the more traditional biomarkers that only focus on presence of certain RNA, DNA or protein molecules and not their activity nor the interaction with the drug.

PamGene has developed its PamChips containing peptide arrays as well as the PS12 instrument to process the chips through years of research and development.

The PamChips are produced at PamGene's manufacturing facilities which allows profound quality control that contribute to reproducibility of the assays. The PS12 instrument is manufactured by a 3rd party with a proven track record in complex instrument development & manufacturing. The instrument received CE marking.